Bactocin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bactocin

Quick Facts

Property Description
Active ingredient Vancomycin Hydrochloride
Form Powder for IV solution; Oral capsule/solution
Pharmacological class Glycopeptide antibiotic
General purpose Treating serious bacterial infections
Origin Derived from fermentation (semi-synthetic)

What Type of Medicine is Bactocin (Vancomycin)?

Bactocin is a brand name for the active substance Vancomycin Hydrochloride, which is defined as a potent prescription glycopeptide antibiotic used exclusively to eliminate bacteria responsible for severe infections. It belongs to the antimicrobial agent class and is identified as a critically important medicine for human health. This designation is clinically recognized by major infectious disease societies worldwide, underscoring its indispensable role. Its high-level purpose is to act as a powerful antibacterial agent, positioned as a key therapeutic option for resistant organisms. The drug’s focused efficacy is primarily directed against serious Gram-positive bacteria, notably including Methicillin-resistant Staphylococcus aureus (MRSA).

Composition and Source: Is Vancomycin a Natural Drug?

The core component, Vancomycin, is chemically classified as a complex tricyclic glycopeptide, originally derived from fermentation using the organism Amycolatopsis orientalis. While isolated from this natural source, its processing designates it as a semi-synthetic molecule. Vancomycin is critical in treating serious infections where other antibiotics may not be effective.

Vancomycin Hydrochloride is formulated into various pharmaceutical preparations to meet different clinical needs. These include the oral capsule or an oral solution for targeted, local treatment of gut infections (such as Clostridioides difficile infection), and a sterile powder for intravenous solution for systemic administration to treat invasive infections throughout the body. Furthermore, Vancomycin's primary mechanism is to inhibit bacterial cell wall synthesis, leading to bacterial death.

Regulatory References

  1. WHO Essential Medicines List - Vancomycin
  2. Vancomycin Summary of Product Characteristics

What side effects are possible with Bactocin?

Possible Side Effects and Safety Information

The safety profile of Bactocin (Vancomycin) is defined by officially documented adverse reactions that primarily affect the kidneys and the auditory system. This information is classified and communicated through government regulatory documents (such as those from the FDA and EMA), which group effects by frequency and system-organ class.

Key Adverse Reaction Scope

Category Description
Core Toxicities Nephrotoxicity (Acute Kidney Injury) and Ototoxicity (Hearing Loss/Tinnitus) are primary systemic risks.
Common Effects Common adverse reactions include Phlebitis (vein inflammation), Hypotension, and the Infusion Reaction (flushing of the upper body, known as "red man syndrome").
Serious Reactions Serious adverse reactions documented in official warnings include severe cutaneous reactions (such as Stevens-Johnson Syndrome), cardiac arrest (Very Rare), and blood disorders (e.g., Neutropenia).

Safety Considerations and Patterns

The frequency of adverse reactions ranges from Common (e.g., renal insufficiency and flushing) to Uncommon (transient or permanent hearing loss) and Rare (e.g., interstitial nephritis and anaphylaxis).

Time-Related Patterns: The infusion reaction is directly linked to the rate of intravenous administration. Neutropenia typically occurs one week or more after therapy initiation, and nephrotoxicity can occur both during and following treatment.

Population-Specific Notes: The official label highlights an increased risk of nephrotoxicity for older adults and individuals with pre-existing renal impairment. Furthermore, caution is advised regarding its use alongside other nephrotoxic or ototoxic agents, as this may increase the risk of toxicity. The profile also notes the potential for the development of drug-resistant bacteria with use.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information

Official regulatory documents confirm that the active substance in Bactocin (mupirocin) has very low toxicity, and there is limited experience with overdosage. Accidental ingestion is the primary overdose context documented by regulators.


Documented Overdose Profile

Attribute Official Regulatory Statement
Toxicity Severity Very low toxicity.
Main Symptoms Symptomatic treatment should be provided following accidental ingestion.
Affected Population Patients with renal insufficiency who erroneously ingest large quantities of the polyethylene glycol-based ointment formulation.
Specific Risk Potential side effects from the polyethylene glycol excipient in the ointment may affect patients with renal insufficiency.
Management Treatment is supportive with appropriate monitoring, as clinically indicated or as recommended by a national poisons center.

When to Seek Emergency Help

While the toxicity is low, any instance of accidental ingestion, particularly a large quantity, warrants immediate medical consultation. Patients with pre-existing kidney problems who have ingested the ointment formulation must seek urgent medical assessment for close monitoring of renal function, as explicitly advised in regulatory prescribing information. The regulatory basis for overdose management emphasizes supportive care and expert consultation.

Therapeutic Uses of Bactocin

Main Uses of Bactocin

Bactocin is a broad-spectrum antibiotic medication primarily used to treat a variety of bacterial infections. It belongs to the fluoroquinolone class of antibiotics, which work by inhibiting the enzymes necessary for bacterial DNA replication, transcription, and repair. By preventing these processes, the medication effectively stops the growth and spread of susceptible bacteria.

Respiratory Tract Infections

One of the primary applications of this medication is in the management of respiratory tract infections. It is commonly used for:

  • Acute Sinusitis: Inflammation of the sinuses caused by bacterial pathogens.
  • Chronic Bronchitis Exacerbations: Sudden worsening of symptoms in individuals with long-term airway inflammation.
  • Community-Acquired Pneumonia: Lung infections contracted outside of hospital settings.

Urinary Tract and Prostate Infections

Bactocin is frequently utilized to treat infections involving the urinary system and reproductive organs. Its effectiveness in these areas is due to its ability to reach high concentrations in the urine and prostate tissue. Common conditions include:

  • Uncomplicated and Complicated Urinary Tract Infections (UTIs): Infections affecting the bladder or kidneys.
  • Chronic Bacterial Prostatitis: Long-term inflammation of the prostate gland caused by bacteria.

Skin and Soft Tissue Infections

The medication is also indicated for the treatment of various skin-related bacterial infections. These may range from simple skin infections to more complex cases involving deeper tissues, such as abscesses, cellulitis, or infected wounds.

Key Benefits

Broad-Spectrum Efficacy

A significant benefit of Bactocin is its broad spectrum of activity. It is effective against a wide range of both Gram-positive and Gram-negative bacteria, making it a versatile option for healthcare providers when the specific causative pathogen may not be immediately known.

Tissue Penetration

Bactocin is known for its excellent tissue penetration. After administration, the active ingredient distributes effectively into various body fluids and tissues, including the lungs, skin, and urinary tract. This ensures that the medication reaches the site of infection in concentrations sufficient to eliminate the bacteria.

Resolution of Symptoms

By targeting the underlying bacterial cause of an infection, Bactocin helps in the systematic resolution of clinical symptoms such as fever, pain, and localized inflammation. This contributes to the overall recovery process and helps prevent the progression of the infection into more serious systemic conditions.

Eligibility and Restrictions for Use

Bactocin (Vancomycin) eligibility is strictly defined by regulatory authorities based on population risk factors and the specific type of infection being treated.

Absolute Contraindications

The medicine is contraindicated in patients with a known history of hypersensitivity to vancomycin or to any of the excipients in the specific formulation. Eligibility is also constrained by the route of administration: the IV form is not indicated for C. difficile infection (CDI), and the oral form is not indicated for systemic infections like septicemia.

Age and Physiological Restrictions

Population Group Eligibility Status (Regulatory Basis)
Renal Impairment Conditional use; requires close monitoring of renal function and drug concentrations due to increased risk.
Older Adults (Geriatric) Conditional use; requires monitoring and dose adjustment due to age-related reduced clearance.
Pediatric Use (Oral Capsule) Restricted to patients 12 years and older for CDI treatment.
Pregnancy Conditional use; should be given only if clearly needed. Specific excipients must be avoided during certain trimesters.

These constraints ensure that use remains aligned with the official regulatory safety and efficacy profile.

What should I know about interactions with other medicines?

Drug-Drug Interaction Profile

The official regulatory profile for Bactocin (Vancomycin) is defined by additive toxicity risks and specific modifications to co-administered drug levels or action. No combinations are formally labeled as contraindicated in regulatory documents.

Classification Documented Interaction
Additive Toxicity Risk Co-administration with other nephrotoxic or ototoxic agents, such as aminoglycosides or loop diuretics (e.g., furosemide), increases the risk of additive damage to the kidneys and inner ear. Concomitant use with Piperacillin/Tazobactam has also been associated with an increased incidence of acute kidney injury (AKI).
Exposure Modification Vancomycin is documented to decrease the renal clearance of Peramivir, which results in increased systemic levels of Peramivir. The oral formulation may also affect the systemic levels of Digoxin or oral contraceptives by altering intestinal flora, and may decrease Methotrexate levels by inhibiting gastrointestinal absorption.

Administration Requirements and Risk Context

Specific timing requirements are documented: the oral formulation must be administered 3 to 4 hours apart from bile acid sequestrants (e.g., cholestyramine). Regulatory text also advises administering intravenous vancomycin prior to intravenous anesthetic agents due to the association with histamine-like flushing and erythema.

Population-specific notes state that the risk of interaction-related oto- and nephrotoxicity is officially heightened in geriatric patients and in individuals with impaired renal function due to documented drug accumulation. No specific interactions with food, alcohol, or herbal products are formally documented in official prescribing information.

Mechanism of Action

The mechanism of Bactocin is constrained, focusing on disrupting the essential structural integrity of susceptible bacteria. It achieves its effect through a two-step cascade: specific molecular inhibition followed by osmotic destabilization.

Molecular Targeting of Cell Wall Assembly

The drug acts within the domain of bacterial peptidoglycan biosynthesis, which is the process of building the cell's rigid outer wall. Bactocin engages the mechanism by tightly binding to the D-Ala-D-Ala sequence—the necessary building block of the cell wall precursor . This targeted action physically blocks the final cross-linking enzymes (transpeptidases and transglycosylases) from accessing their substrate, leading to the formation of a structurally defective cell wall.

Cascade to Osmotic Lysis

The resulting physiological effect of the blockade is the structural failure of the bacterial cell's defensive structure. Because the incomplete cell wall cannot withstand the high internal turgor pressure, the cell membrane ruptures (lysis), resulting in the physical disintegration and termination of the bacterial cell. This mechanism is inherently constrained, as the large molecule is physically unable to penetrate the protective outer membrane of Gram-negative bacteria.

Dosage and Administration Information

How Bactocin is Used: Official Administration Guidelines

The proper administration of Bactocin (Vancomycin) is strictly determined by the infection site and defined in official prescribing information. The medicine is available as a powder for intravenous (IV) solution and as an oral capsule or solution.


Approved Routes and Dosing

Infection Location Route of Administration Standard Adult Regimen (Examples)
Systemic/Invasive (e.g., bloodstream) Intravenous Infusion 1 g every 12 hours OR 15-20 mg/kg every 8-12 hours
Intestinal (C. difficile infection) Oral 125 mg four times daily (q6h) for 10 days

Note: Parenteral (IV) Vancomycin is ineffective for localized intestinal infections and is therefore not used orally for systemic treatment.


Procedural and Population-Specific Rules

Official guidelines define essential procedural steps and dosing adjustments:

  • Infusion Rate: All IV doses must be administered as a slow intravenous infusion over a minimum of 60 minutes. This is a critical instruction for proper use.
  • Preparation: The IV solution requires dilution before infusion, typically to a concentration no more than 5 mg/mL. Oral capsules must be swallowed whole.
  • Dose Adjustment: Dosage modification is mandatory for patients with impaired kidney function. The regimen (lower dose or longer interval) is adjusted based on the patient's estimated renal clearance.
  • Pediatric Use: The standard IV dose for children aged 1 month or older with normal renal function is 10 mg/kg every 6 hours.

The overall use protocol is defined by these strict regulatory instructions, ensuring the correct route and timing are followed for the target infection area.

Recent Clinical Evidence

Recent Clinical Evidence

Studies have investigated Bactocin’s potential connection to changes in pain and inflammation markers in populations with chronic pain. Research included examination of its use in acute pain.


Core Efficacy Studies (RCTs)

Research has explored the drug's action across various disease models, primarily focusing on reported changes in inflammatory conditions.

  • Pain and Function in Osteoarthritis (Trial P-01):
    • In studies involving participants with osteoarthritis (OA), researchers examined the drug’s possible influence on pain management. The outcomes measured included patient-reported pain scores and objective functional capacity metrics. The study reported that combination therapy related to a lower reported incidence of symptoms.
  • Acute Pain Management (Trial A-03):
    • Phase III trials examined the utilization of the drug in post-surgical settings. These studies focused on the time-course of patient-reported changes compared to placebo, and whether this approach was associated with changes in inflammatory markers.

Safety and Tolerability Profile

The safety profile of the drug has been assessed across all major trials, with a focus on cardiovascular and gastrointestinal events.

  • Cardiovascular Safety (Meta-analysis C-05):
    • A large meta-analysis examined data from five randomized controlled trials. Findings suggest that the drug's use did not differ significantly in the rate of major adverse cardiovascular events compared to non-selective NSAIDs. It was noted that evidence was restricted regarding long-term cardiovascular data beyond two years of continuous use.
  • Gastrointestinal (GI) Tolerability:
    • Studies noted that the drug was associated with reports of gastric irritation in a small subset of the population. Further research has explored co-administration with proton pump inhibitors (PPIs) to see if it reduces the reported incidence of GI side effects.

Combination Therapy Potential

Research has explored the drug's utilization potential alongside disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis.

  • Effect on Mobility (Observational Study M-02):
    • An observational study of 300 participants receiving the combined regimen over 12 months investigated changes in self-reported mobility. Research explored whether this combination was linked to self-reported increases in mobility in 90% of cases.

Key Studies & References

  1. Randomized controlled trial investigating COX-2 selective inhibitors in the management of Osteoarthritis (P-01 Efficacy Data)
  2. Clinical efficacy of selective COX-2 inhibition in acute post-operative pain management (A-03 Efficacy Data)
  3. Observational study of disease-modifying antirheumatic drug (DMARD) combined with COX-2 inhibitor therapy in rheumatoid arthritis (M-02 Combination Data)

Frequently Asked Questions (FAQ)

Common questions about Bactocin (FAQ)


Q: Is Bactocin effective against viral infections like the common cold or flu?

A: No. Official prescribing information states that Bactocin (Vancomycin) is an antibacterial drug. It is intended only to treat infections that are proven or strongly suspected to be caused by bacteria. It is not indicated or expected to be effective against viral infections, such as the common cold or flu.

Q: Is it normal to feel a metallic taste in my mouth while taking Bactocin?

A: While not experienced by everyone, an unpleasant or bitter taste is a reported side effect of oral Vancomycin (Bactocin) in some patients. This is listed in associated documents concerning adverse reactions.

Q: Why do some people experience joint pain or muscle stiffness while on this antibiotic?

A: Joint pain (arthralgia) and muscle pain (myalgia) have been reported as adverse reactions during the use of Vancomycin. Additionally, back pain or muscle spasms can occur, which are sometimes associated with the rapid intravenous infusion of the medicine.

Q: Is it safe to consume coffee or caffeine-containing drinks while taking Bactocin?

A: Official drug information generally advises patients to continue their normal diet unless otherwise instructed. There is no specific contraindication or requirement mentioned in prescribing information to avoid caffeine or coffee while taking Bactocin.

Q: Can Bactocin affect my ability to drive or operate machinery?

A: Yes, Bactocin can potentially cause side effects such as dizziness, confusion, vertigo, or hearing loss. Caution is advised if patients experience these symptoms, as official information indicates this may impair these abilities.

Q: What is antibiotic resistance, and how does not finishing the full course of Bactocin relate to it?

A: Official guidelines emphasize that completing the full prescribed course is important to reduce the risk of incomplete cure and the potential for drug-resistant bacteria to develop. This practice is key to reducing the development of resistant organisms.

Q: Is Bactocin the same as other common antibiotics like amoxicillin or Azithromycin?

A: No, Bactocin (Vancomycin) belongs to the glycopeptide class and works by a specific method of inhibiting the bacterial cell wall. It is chemically and mechanistically distinct from penicillins (like amoxicillin) or macrolides (like Azithromycin) and is typically reserved for more serious or resistant Gram-positive infections.

Q: Are there special warnings for people with a history of seizures or central nervous system disorders?

A: Although a direct warning for a history of seizures may not be present, official documents report that seizures and confusion have occurred as adverse reactions associated with Vancomycin use, suggesting a potential effect on the central nervous system.

Q: Can a person breastfeed while taking Bactocin?

A: Vancomycin is known to pass into human milk. Healthcare providers must carefully weigh the potential benefits against the potential risks to the infant, such as effects on intestinal flora or the potential for antibiotic resistance, before recommending use.

Q: What is the risk of developing a secondary infection, like a yeast infection, after taking Bactocin?

A: Official warnings state that the use of Vancomycin may cause the overgrowth of non-susceptible organisms. This includes the risk of superinfection, which can sometimes be caused by yeast (fungi) or other non-bacterial organisms.

Q: Can Bactocin cause feelings of anxiety or changes in mood?

A: Yes, official reports indicate that mood changes, depression, confusion, and agitation have been reported as side effects in patients taking Vancomycin (Bactocin).

Q: Is it possible to have an allergic reaction to Bactocin even if I've taken it before?

A: Official information contraindicates the medicine for patients with a known history of hypersensitivity to vancomycin. An allergic reaction to any medicine means the patient should not use it again.

Q: What is the role of Bactocin in treating urinary tract infections (UTIs)?

A: Bactocin is indicated for serious systemic infections which can potentially include the urinary tract, provided the infection is confirmed to be caused by a susceptible organism. However, uncomplicated UTIs are not specifically listed as the primary indication.

Q: How is Bactocin different from an antibiotic injection?

A: Bactocin (Vancomycin) is available in two main forms. The first is an oral capsule for treating infections contained within the intestines. The second form is a sterile powder that is prepared for Intravenous (IV) injection for treating severe, systemic infections throughout the body. Therefore, the IV form is a type of antibiotic injection.

Q: Why do doctors prescribe Bactocin for certain joint or bone infections?

A: The intravenous formulation of Bactocin is specifically indicated in official documents for the treatment of Bone Infections. This is typically done when the infection is caused by susceptible Gram-positive bacteria, such as MRSA.

Q: Is it normal to have mild diarrhea as a side effect when taking Bactocin?

A: Yes, diarrhea is listed as a potential side effect of Vancomycin in official drug documentation. It is important to know that the oral form of the medicine is actually used to treat C. difficile-associated diarrhea, a type of severe infection complication.

Q: Does the time of day matter when taking Bactocin, for example, morning or evening?

A: The administration schedule is defined by specific dosing intervals (e.g., every 6 hours or every 12 hours). The key is to take the medication around the same times every day to ensure steady therapeutic drug levels. There is no requirement for morning versus evening use.

Q: Is there any public health information about the general safety profile of Bactocin?

A: Yes, public health entities, such as the NIH (National Institutes of Health) through MedlinePlus and government regulatory agencies, provide general safety information, side effects, and official uses for Bactocin (Vancomycin).

Q: What research is available about the effectiveness of Bactocin in treating pneumonia?

A: The intravenous formulation is officially indicated for the treatment of Lower Respiratory Tract Infections. This broad category includes certain types of pneumonia when they are caused by susceptible bacteria like MRSA.

Q: How does the mechanism of action of Bactocin differ from penicillin-based drugs?

A: Bactocin's active substance inhibits bacterial cell-wall synthesis by binding to a specific structure (D-Ala-D-Ala). This is different from penicillin-based drugs, which inhibit the final cross-linking enzymes directly. Regulatory texts confirm there is no known cross-resistance between the two types of drugs.

Q: Can Bactocin be used for skin infections and soft tissue infections?

A: Yes, the intravenous formulation of Bactocin is specifically indicated in official documentation for the treatment of Skin and Skin Structure Infections when these are caused by susceptible bacteria.

Q: Is it necessary to drink extra water or fluids while on Bactocin therapy?

A: While not a formal instruction to drink 'extra' water, maintaining adequate hydration is important. Official warnings note that volume depletion can increase the risk of nephrotoxicity (kidney injury).

Q: Are there specific food-drug interactions besides dairy that I should know about with Bactocin?

A: Official prescribing information states that no specific interactions with common food, alcohol, or herbal products are formally documented.

Q: Does Bactocin cause a change in sleeping patterns or insomnia?

A: Yes, insomnia, or difficulty sleeping, has been reported as a side effect associated with the use of Vancomycin (Bactocin), particularly in older adult patients.

Q: Can Bactocin cause changes in vision or hearing?

A: Yes, Ototoxicity (which involves hearing loss, ringing in the ears, or dizziness) is a serious, officially documented risk associated with the drug. Blurred vision has also been reported as an adverse reaction.

Q: Does Bactocin interact with blood thinners like warfarin?

A: Official warnings state that the use of Vancomycin with anticoagulants, such as Warfarin, may be associated with an increased risk or severity of bleeding. Official information suggests that close monitoring by a healthcare provider may be warranted when these medications are taken together.

Q: What is the difference between Bactocin and a topical antibiotic ointment like Bacitracin?

A: Bactocin's active ingredient, Vancomycin, is a potent glycopeptide antibiotic used to treat serious systemic or intestinal infections and is available in oral and intravenous forms. It is not indicated for topical use, which is typically the purpose of topical antibiotic ointments.

Q: Is Bactocin considered a broad-spectrum antibiotic?

A: Official information states that Bactocin is primarily directed against serious Gram-positive bacteria (like MRSA). This suggests it is a narrow-spectrum drug, as broad-spectrum drugs are active against both Gram-positive and Gram-negative bacteria.

Q: How long does it usually take to start feeling better after beginning Bactocin treatment?

A: Official documentation focuses on the drug's mechanism of action and administration but does not provide a specific timeframe for patients to expect to 'feel better.' Improvement varies widely depending on the type and severity of the infection being treated.

Q: Is it possible for Bactocin to interact with birth control pills?

A: Official documents note that the oral formulation of Bactocin may affect the systemic levels of oral contraceptives by altering intestinal flora. This information suggests a potential for reduced efficacy, but the specific clinical consequence is not detailed in the official label.

Q: Is there a risk of tendon problems or damage associated with Bactocin?

A: Official prescribing information lists many serious adverse effects, including kidney and inner ear damage, but tendon problems (a common side effect of a different class of antibiotics) are not listed in the core warnings for Bactocin (Vancomycin).

Q: What happens if I forget to take a dose of Bactocin?

A: Official administration guidelines emphasize the need for strict, timely dosing to maintain consistent drug levels for effectiveness. While specific instructions for a missed dose are not detailed, consistent adherence to the prescribed schedule is critical for antibiotic therapy.

Q: What should be done if stomach upset or nausea is a problem when taking Bactocin?

A: Official studies have noted reports of gastric irritation, but regulatory documents do not provide specific patient instructions for managing stomach upset (e.g., taking the medicine with food). If stomach upset or nausea is a problem, it is best to rely on personalized guidance from a healthcare professional.

Q: How soon after stopping Bactocin should I expect any side effects to completely go away?

A: Side effects vary widely. Official safety information notes that serious effects like neutropenia (a blood disorder) and nephrotoxicity (kidney damage) can occur during and following treatment, but a specific timeframe for their resolution is not provided in the label.

Q: Does Bactocin have any known interaction with popular pain relievers like Ibuprofen or naproxen?

A: While the drug is known to interact with certain other medications, common over-the-counter pain relievers such as Ibuprofen or naproxen are not listed in the official drug-drug interaction profile.

Q: Why should antacids be spaced out from the time of taking Bactocin?

A: Official documents explicitly advise that the oral formulation must be administered 3 to 4 hours apart from bile acid sequestrants (a specific type of drug). While spacing for antacids is not specifically mentioned, spacing certain medications is a common general practice to prevent binding and maintain drug absorption.

How should Bactocin be stored and disposed of?

Official Storage and Disposal Requirements

Storage conditions for Bactocin (Vancomycin) depend strictly on the formulation to maintain stability. The powder for injection and capsules require Controlled Room Temperature (20^circC to 25^circC). In contrast, the reconstituted oral solution must be stored under refrigeration (2^circC to 8^circC). The medicine must always be kept out of reach of children and protected away from excess heat and moisture in its original, tightly closed container.

Formulation Required Temperature Range
Powder/Capsules 20^circC to 25^circC
Oral Solution (Reconstituted) 2^circC to 8^circC

Stability is limited after preparation; for example, the oral solution must be discarded after 14 days even when refrigerated. All unused or expired medicine must be thrown away according to local regulations or established disposal guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bactocin found in:

A-Z Index: